ABOUT

A bridge between Singapore innovation
and U.S. clinical access

NUHTA is a structured acceleration program developed in partnership with the National University Health System (NUHS) of Singapore. It gives select healthtech companies a direct pathway into HTA's coalition of U.S. hospital and health system partners, providing the clinical studies and real-world evidence they need to enter the U.S. market.

HTA has spent over a decade building the relationships and infrastructure that make guaranteed U.S. clinical engagement possible. NUHTA brings that capability to some of the most promising Singapore-based healthtech companies.

Program structure

How it works

Each company in the cohort receives three integrated tracks of support, delivered over the course of the program year.

Education

A structured curriculum covering U.S. market entry, regulatory pathways, clinical study design, reimbursement strategy, and commercialization fundamentals.

U.S. Strategic Plan Development

1:1 sessions with SMEs for the development of custom, US-focused strategic plans in five areas: reimbursement, regulatory, commercialization, clinical and fundraising.

Clinical engagement

Facilitated pilot projects and clinical trials with HTA's U.S. clinical partner coalition. Each company completes at least one clinical study during the program year.

Why HTA

Not introductions. Execution.

Many programs connect companies to health systems. HTA goes further: we manage the U.S. clinical engagement end-to-end, so companies bypass the time-consuming and expensive effort of developing clinical partners.

GUARANTEED CLINICAL ENGAGEMENT

Every NUHTA company enters the program with a commitment to at least one U.S. clinical study. HTA identifies clinical champions at partner institutions and manages the relationship from match through study completion.

**A PROVIDER-DRIVEN MODEL**

HTA's clinical partners participate by choice and are actively engaged in the program. That's what makes the guarantee credible. Partner institutions are opening their doors to companies they've agreed to work with — not receiving a cold introduction.

DEEP CLINICAL SUPPORT

HTA's in-house Clinical Trial Manager provides hands-on support for study design, protocol development and site coordination. For many companies, this reduces or eliminates the need to engage an external CRO for their U.S. clinical work.

**END-TO-END PROGRAM INFRASTRUCTURE**

From legal onboarding and clinical partner matching to education curriculum and strategic advising, HTA manages every component of the U.S. program. Companies arrive and get to work — the infrastructure is already in place.

Program outcomes

What companies ultimately gain

At the end of the program year, each company has a tangible set of assets built through direct engagement with U.S. clinical partners and HTA's team.

U.S. clinical evidence

Documented study results from credentialed U.S. institutions, suitable for regulatory submissions, investor decks, and commercial conversations with U.S. buyers.

Institutional relationships

Direct relationships with U.S. hospital and health system partners — built through the program, with the potential to convert pilot projects into commercial contracts.

Investor connections

Each cohort company has the opportunity to pitch to US-based venture capital firms, developing meaningful relationships with capital sources.

U.S. market clarity

A practical understanding of U.S. healthcare procurement, reimbursement pathways, and regulatory requirements — built through advisor-led development of US-focused strategic plans and direct engagement with providers.